San Diego, California--(Newsfile Corp. - October 21, 2025) - Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, announced today that it will be presenting at the 19th annual Main Event on Tuesday, October 21st at 4:00 PM PT at the Hotel del Coronado in San Diego, California. Jim Joyce, CEO and Inventor will be giving the presentation.
"The Main Event is a culmination of over 25 years of hard work and passion for small company investing. There is no organization on planet Earth that cares more about small companies succeeding than LD. To be able to connect with our community in one of the most beautiful settings imaginable brings me considerable joy. We look forward to welcoming all of our patrons and ensuring that they have a wonderful time," stated Chris Lahiji, Founder of LD Micro.
Event: LD Micro Main Event XIX
Date: Tuesday, October 21st
Time: 4:00 PM
Register to watch the virtual presentation here.
Summary of LD Micro Main Event XIX
The 2025 LD Micro Main Event XIX will run from October 19th to the 21st at the Hotel del Coronado in San Diego, California.
The first day will consist of registration, keynote speakers, and some gorgeous views of the Pacific. It will be followed by two full days of company presentations and one-on-one investor meetings concluded with a closing reception.
This three-day event will feature around 120 companies, presenting in half-hour increments, and attending private meetings with investors.
About Sigyn Therapeutics, Inc.
Sigyn Therapeutics is developing dialysis-like therapies to address cardiovascular disease and cancer. Sigyn CardioDialysis™ is a first-in-class blood purification technology being advanced to treat cardiovascular disease, the leading cause of global deaths. CardioDialysis™ is designed to reduce the circulating presence of inflammatory molecules that drive cardiovascular disease progression while simultaneously targeting cholesterol transporting lipoproteins that contribute to heart attacks, strokes, and other major adverse cardiovascular events (MACE). The Company’s development pipeline includes ImmunePrep™ to optimize the delivery of immunotherapeutic antibodies; ChemoPrep™ to enhance the targeted delivery of chemotherapy; and ChemoPure™ to reduce chemotherapy toxicity. To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com
About LD Micro
LD Micro is dedicated to being the definitive resource in the small-cap space. From its industry-recognized index and robust data to hosting some of the most influential events each year, LD Micro’s mission is to provide unparalleled access and insight for those seeking the next generation of great companies.
To learn more about LD Micro, visit:
http://www.ldmicro.com
To learn more about Freedom US Markets LLC, visit:
https://www.freedomcapmkts.com/
To present or register, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..
For further information on Sigyn Therapeutics, Inc.:
Sigyn Therapeutics, Inc.
Jim Joyce
619-368-2000
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.sigyntherapeutics.com
| Last Trade: | US$1.70 |
| Daily Volume: | 0 |
| Market Cap: | US$2.740M |
December 12, 2023 November 14, 2023 October 04, 2023 August 14, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
